Mnemo Therapeutics

Mnemo Therapeutics is a biotechnology company based in Paris, founded in 2019.

The company focuses on developing cell therapies and immunotherapies aimed at providing accessible cures for solid tumors and blood cancers. It enhances the body's ability to detect and eliminate cancer by identifying new tumor-specific targets known as E-antigens, derived from the dark genome. The company's core platform, EnfiniT, is a drug discovery engine that combines innovative E-antigen identification with tools designed to improve CAR T-cell memory and persistence. This approach aims to achieve deeper clinical responses compared to existing cell therapies. Mnemo Therapeutics utilizes both computational and wet-lab techniques, collaborating with leading research institutions like Institut Curie and Memorial Sloan Kettering Cancer Center to advance next-generation CAR T-cell therapies. The company develops various therapeutic modalities, including cell therapies, T-cell engagers, antibody-drug conjugates, and vaccines, focusing on both autologous and allogeneic cell manufacturing.